Avid Bioservices Inc (CDMO)

[stoneroad]

I'm now backtracking a bit and soon may be eating crow.

Biomarkers are classified as either prognostic, predictive or pharmacodynamic.

Prognostic biomarkers distinguish indolent from aggressive tumors, thus identifying which patients to treat.

Predictive biomarkers identify those patients who will derive benefit from a particular therapy.

Pharmacodynamic biomarkers identify whether and at which dose appropriate target modulation is achieved.

My assumption has been that the biomarker in the Peregrine PR was of the predictive nature - thus the reference to subsets. After reading more about biomarkers, and if the biomarker in question is actually Pharmacodynamic, then IMO and theoretically speaking, CP (and others) may in fact be correct in stating that the PR is addressing the entire treatment arm in SUNRISE and not just a subset.

I hope he's spot on. Either way, we know in 9 short days.